Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.38 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | SHMT2 | P34897 | 2/20 | 0.35 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.35 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11190782 | 0.73 | AKR1B1 (0.45) | ALDH1A1LMNAHSD17B10AKR1B1MEN1 | |
| SCHEMBL29478385 | 0.72 | CA12 (0.54) | ALDH1A1LMNAHSD17B10HTTMEN1 | |
| SCHEMBL1818689 | 0.72 | ALDH1A1 (0.47) | ALDH1A1USP2LMNAHSD17B10BBOX1 | |
| SCHEMBL29367675 | 0.72 | CA12 (0.54) | ALDH1A1LMNAHSD17B10HTTMEN1 | |
| SCHEMBL298855 | 0.72 | CA12 (0.54) | ALDH1A1LMNAHSD17B10HTTMEN1 | |
| SCHEMBL42287 | 0.72 | CA12 (0.54) | ALDH1A1LMNAHSD17B10HTTMEN1 | |
| SCHEMBL409050 | 0.72 | CA12 (0.54) | ALDH1A1LMNAHSD17B10HTTMEN1 | |
| SCHEMBL42286 | 0.72 | CA12 (0.54) | ALDH1A1LMNAHSD17B10HTTMEN1 | |
| SCHEMBL1818692 | 0.72 | ALDH1A1 (0.47) | ALDH1A1USP2LMNAHSD17B10BBOX1 | |
| SCHEMBL837337 | 0.72 | PKM (0.58) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 435 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617815-B2 | Barcoded XTEN polypeptides and compositions thereof, and methods for making and using the same | AMUNIX PHARMACEUTICALS, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-12589134-B2 | Compositions and methods of use of interleukin-10 in combination with immune check-point pathway inhibitors | ELI LILLY AND COMPANY (US) | 2026-03-31 | — | — | US | disclosed |
| US-20260071177-A1 | ACCELERATION OF STEM CELL DIFFERENTIATION | UNIV MINNESOTA (US) | 2026-03-12 | — | — | US | disclosed |
| US-12570981-B2 | Genetically modified mouse with conditional deletion of LRP1 in oligodendrocytes | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2026-03-10 | — | — | US | disclosed |
| US-12545739-B2 | Compositions and methods for making and using bispecific antibodies | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2026-02-10 | — | — | US | disclosed |
| US-20260021165-A1 | Extracellular Carboxylesterase 2 (CES2) for the Treatment of Metabolic Disease | UNIV LELAND STANFORD JUNIOR (US) | 2026-01-22 | — | — | US | disclosed |
| US-20250376532-A1 | STRATEGY FOR HIGHLY SUPERIOR DR5 ACTIVATION INCLUDING IN TUMORS AND CANCERS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250340624-A1 | COMPOSITIONS AND METHODS FOR DETECTING AND REGULATING FIBRONECTIN-INTEGRIN INTERACTION AND SIGNALING | GEORGIA TECH RESEARCH CORPORATION (GE) | 2025-11-06 | — | — | US | disclosed |
| US-20250332285-A1 | ENGINEERING SUICIDE GENE APPROACHES TO IMPROVE CHEMOTHERAPEUTIC RESPONSE IN CANCER | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250332246-A1 | ENHANCED EXPRESSION VIA AUTOTRANSPORTERS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-10-30 | — | — | US | disclosed |
| US-20050027105-A9 | Multimeric proteins for use in the treatment and detection of cell proliferative disorders | BRACCO SUISSE SA (CH) | 2005-02-03 | — | — | US | disclosed |
| EP-1482987-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | BRACCO INTERNATIONAL B.V. (NL) | 2004-12-08 | — | — | EP | disclosed |
| US-20040210041-A1 | Multimeric proteins for use in the treatment and detection of cell proliferative disorders | ARBOGAST CHRISTOPHE (FR) | 2004-10-21 | — | — | US | disclosed |
| WO-2004078778-A2 | PEPTIDES THAT SPECIFICALLY BIND HGF RECEPTOR (cMet) AND USES THEREOF | DYAX CORP. (US) | 2004-09-16 | — | — | WO | disclosed |
| WO-2004065621-A1 | KDR AND VEGF/KDR BINDING PEPTIDES AND THEIR USE IN DIAGNOSIS AND THERAPY | DYAX CORP. (US) | 2004-08-05 | — | — | WO | disclosed |
| WO-2004064595-A2 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | BRACCO INTERNATIONAL BV (NL) | 2004-08-05 | — | — | WO | disclosed |
| US-20040018974-A1 | Multivalent constructs for therapeutic and diagnostic applications | BRACCO SUISSE SA (CH) | 2004-01-29 | — | — | US | disclosed |
| WO-2003084574-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | BRACCO INTERNATIONAL BV (NL) | 2003-10-16 | — | — | WO | disclosed |
| US-20030181457-A1 | Chemical compounds | LILLY ICOS LLC | 2003-09-25 | — | — | US | disclosed |
| WO-2003074005-A2 | KDR AND VEGF/KDR BINDING PEPTIDES AND THEIR USE IN DIAGNOSIS AND THERAPY | DYAX CORP. (US) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12589134-B2 | Compositions and methods of use of interleukin-10 in combination with immune check-point pathway inhibitors | PDCD10, CD274, PDCD1LG2 | ALDH1A1 2319/4885USP2 3086/4885LMNA 2969/4885 |
| US-20260021165-A1 | Extracellular Carboxylesterase 2 (CES2) for the Treatment of Metabolic Disease | CES1, CES2, CETP | ALDH1A1 2690/4885USP2 54/4885LMNA 3528/4885 |
| US-20250332285-A1 | ENGINEERING SUICIDE GENE APPROACHES TO IMPROVE CHEMOTHERAPEUTIC RESPONSE IN CANCER | ST14, MAPK14, MAP3K14 | ALDH1A1 3979/4885USP2 2770/4885LMNA 2318/4885 |
| US-12570981-B2 | Genetically modified mouse with conditional deletion of LRP1 in oligodendrocytes | LDLR, MSR1, LOXL1 | ALDH1A1 2383/4885USP2 1071/4885LMNA 577/4885 |
| US-20250376532-A1 | STRATEGY FOR HIGHLY SUPERIOR DR5 ACTIVATION INCLUDING IN TUMORS AND CANCERS | TNFRSF9, TNFRSF1A, TNFSF11 | ALDH1A1 4593/4885USP2 2802/4885LMNA 3607/4885 |
| US-12545739-B2 | Compositions and methods for making and using bispecific antibodies | TNFRSF9, TNFRSF1A, FOLR1 | ALDH1A1 3474/4885USP2 2469/4885LMNA 2043/4885 |
| US-12617815-B2 | Barcoded XTEN polypeptides and compositions thereof, and methods for making and using the same | SPPL2B, PTMS, ANPEP | ALDH1A1 3997/4885USP2 560/4885LMNA 2031/4885 |
| US-20030181457-A1 | Chemical compounds | ABCG2, SDHA, CYP11B1 | ALDH1A1 126/4885USP2 4829/4885LMNA 1866/4885 |
| US-20260071177-A1 | ACCELERATION OF STEM CELL DIFFERENTIATION | FGFR2, FGF2, FGF1 | ALDH1A1 1177/4885USP2 1465/4885LMNA 2877/4885 |
| US-20050027105-A9 | Multimeric proteins for use in the treatment and detection of cell proliferative disorders | MKI67, TP53, VHL | ALDH1A1 4127/4885USP2 2036/4885LMNA 912/4885 |
| US-20040018974-A1 | Multivalent constructs for therapeutic and diagnostic applications | CD47, BCR, CD44 | ALDH1A1 4079/4885USP2 1645/4885LMNA 1815/4885 |
| US-20250340624-A1 | COMPOSITIONS AND METHODS FOR DETECTING AND REGULATING FIBRONECTIN-INTEGRIN INTERACTION AND SIGNALING | FN1, IGSF11, VSIG8 | ALDH1A1 4673/4885USP2 3415/4885LMNA 534/4885 |
| US-20040210041-A1 | Multimeric proteins for use in the treatment and detection of cell proliferative disorders | MKI67, TP53, VHL | ALDH1A1 4127/4885USP2 2036/4885LMNA 912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.